Article

Regeneron, Genentech Extend Anti-VEGF Payment Terms

In response to the COVID-19 pandemic, both companies have temporarily extended physician payment terms for their anti-VEGF purchases from authorized distributors. 

Related

In response to the COVID-19 pandemic, both Regeneron (aflibercept; Eylea) and Genentech (ranibizumab; Lucentis) have temporarily extended physician payment terms for their anti-VEGF purchases from authorized distributors. In the case of Eylea, physicians may be temporarily eligible for payment terms of up to 150 days (previously 100 days), subject to distributor qualification. Ophthalmologists are urged to verify the timing and specific dating terms that apply to their offices with their authorized distributors of record. This has no impact on current Eylea return policies.

Regeneron implemented these new temporary terms April 1. These terms apply retroactively for Eylea (vial or prefilled syringe) purchased on or after March 1, 2020. The temporary payment terms are subject to change and will be evaluated as the COVID-19 situation evolves.

Genentech said it will temporarily extend physician payment terms for Lucentis purchases from 60 days to 120 days, according to a company news release. Purchases from April 1, 2020, as well as retroactively for purchases made on or after March 1, 2020, will be eligible for the extension. Physicians should contact their respective specialty distributor with questions or to verify the new terms, the company said in a news release.